NOVALTEX 1

*Key Benefits of Novaltex 1* • *Precise estrogen control:* Effectively inhibits the aromatase enzyme, reducing the conversion of testosterone to estradiol • *Gynecomastia prevention:* Helps prevent estrogen-induced breast tissue development during hormonal cycles • *Reduced water retention:* Decreases subcutaneous water retention, improving muscle definition • *Drier, more defined physique:* Promotes a more vascularized and aesthetically superior appearance • *Third-generation inhibitor:* Non-steroidal, highly selective and potent with manageable side effects • *Essential complement:* Ideal for testosterone, methandrostenolone, and other aromatizable compound cycles • *Estrogenic effect prevention:* Reduces the appearance of acne, mood swings, and fat gain associated with excess estrogen

*How does Novaltex 1 work?* Novaltex 1 contains *Anastrozole USP*, a third-generation non-steroidal aromatase inhibitor that works in the following ways: • *Aromatase inhibition:* Blocks the aromatase enzyme, responsible for converting androgens (testosterone) into estrogens (estradiol) in adipose tissue and other peripheral tissues • *Serum estradiol reduction:* Decreases blood estradiol levels by up to 80% with daily doses of 1 mg, maintaining them in optimal ranges for muscle development • *Non-steroidal profile:* Unlike first-generation inhibitors, it does not affect the production of other steroidal hormones, offering greater selectivity • *Hormonal axis effect:* Helps maintain a favorable hormonal balance, reducing negative feedback on the hypothalamic-pituitary-gonadal axis • *No androgenic effects:* Does not present androgenic, estrogenic, or progestational activity, minimizing unwanted side effects This mechanism of action makes Novaltex 1 the ideal complement for *cycles with aromatizable compounds, allowing maintained controlled estrogenic levels for cleaner, more defined muscle development*.

Usage Guide for Novaltex 1 • Recommended dosage in testosterone cycles: 0.5 mg to 1 mg daily (1/2 to 1 tablet), depending on testosterone dosage and individual sensitivity • Suggested starting dose: Begin with 0.5 mg every other day to assess tolerance and response, adjusting as needed • Cycle duration: Use throughout the entire cycle of aromatizable compounds, from day one until the start of post-cycle therapy (PCT) • Schedule: Administer at the same time daily to maintain stable plasma levels • Recommended cycle: Essential as a complement in testosterone cycles (250-750 mg/week), methandrostenolone, and other aromatizing compounds • Post-cycle therapy (PCT): Reduce or discontinue at the start of PCT when SERMs (Tamoxifen, Clomiphene) are introduced • Warning: Do not exceed 1 mg daily without supervision. Consider monitoring estradiol levels through blood tests. Consult with a healthcare professional before use.

Composition of Novaltex 1 • Active Ingredient: Anastrozole USP 1 mg per tablet • Excipients: Lactose monohydrate, microcrystalline cellulose, pregelatinized corn starch, magnesium stearate, colloidal silicon dioxide • Presentation: 70 tablets per package • Certification: Manufactured under USP (United States Pharmacopeia) standards • Quality control: Purity and potency testing performed by independent laboratories • Storage: Store at controlled room temperature 20°-25°C (68°-77°F), protect from light and moisture

Onset time and expected results • Onset time: Aromatase inhibition begins within 24 hours after administration, with maximum estradiol reduction achieved in approximately 3-5 days • Results at 1-2 weeks: Visible reduction in water retention, improved muscle definition, and decreased nipple sensitivity • Results at 3-4 weeks: Stable estrogenic control, drier and more vascularized physique, reduction in estrogenic side effects • Results at 6-8 weeks: Maintenance of an optimal hormonal environment throughout the cycle, cleaner and more defined muscle development • Expected results (full cycle): Serum estradiol reduction: 60-80% with 1 mg/day dose Water retention reduction: Notable Definition and vascularity improvement: Significant Gynecomastia prevention: Effective with adequate dosing Estrogenic effect control: Optimal

*Clinical research and laboratory testing* • *Clinical studies:* Anastrozole has been extensively studied in clinical trials. It has been shown to reduce serum estradiol levels by 80% with 1 mg daily doses in postmenopausal breast cancer patients • *Pharmacological profile:* Highly selective third-generation non-steroidal inhibitor for the aromatase enzyme, without significant effect on cortisol or aldosterone synthesis • *Athletic applications:* Used by athletes and bodybuilders to control the conversion of exogenous testosterone to estrogen, maintaining a favorable hormonal environment for muscle development • *3rd party testing:* Our batches are subjected to purity and potency testing by certified independent laboratories • *Certifications:* - Manufactured under GMP (Good Manufacturing Practices) standards - USP quality control - Stability and shelf-life testing • *Scientific references:* Available upon request for healthcare professionals